Stockreport

Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome

Albireo Pharma, Inc.  (ALBO) 
Last albireo pharma, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.albireopharma.com/investor-relations
PDF BOSTON, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modul [Read more]